WO1997021693A1 - Stereoselective process - Google Patents

Stereoselective process Download PDF

Info

Publication number
WO1997021693A1
WO1997021693A1 PCT/US1996/019782 US9619782W WO9721693A1 WO 1997021693 A1 WO1997021693 A1 WO 1997021693A1 US 9619782 W US9619782 W US 9619782W WO 9721693 A1 WO9721693 A1 WO 9721693A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
coor
group
recited
Prior art date
Application number
PCT/US1996/019782
Other languages
English (en)
French (fr)
Inventor
Paul N. Devine
Richard M. Heid, Jr.
David M. Tschaen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602833.7A external-priority patent/GB9602833D0/en
Priority claimed from GBGB9608928.9A external-priority patent/GB9608928D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP09522200A priority Critical patent/JP2000501737A/ja
Priority to EP96943713A priority patent/EP0869950A1/en
Priority to AU12878/97A priority patent/AU703380B2/en
Publication of WO1997021693A1 publication Critical patent/WO1997021693A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the "R" stereochemistry can be obtained utilizing (S)-ethyl lactate as the chiral auxiliary although diastereoselectivities are significantly lowered in comparison to pantolactone (60-75%).
  • the instant invention relates to a highly stereoselective coupling reaction mediated with a pyrrohdine derived lactamide as a chiral auxiliary.
  • This invention relates to a method for the stereoselective synthesis of a 2-aryloxycarboxylic acid using a chiral auxiliary, such as a compound of formula I to enhance the stereoselectivity of the alkylation of the ⁇ -halo acid with an aryloxy group.
  • a chiral auxiliary such as a compound of formula I to enhance the stereoselectivity of the alkylation of the ⁇ -halo acid with an aryloxy group.
  • the invention also relates to a novel compound of formula:
  • R a is (Cl -C6)-alkyl, phenyl, or cyclohexyl, which is useful as a chiral auxiliary.
  • R a is (Cl -C6)-alkyl, phenyl, or cyclohexyl, which is useful as a chiral auxiliary.
  • X is Cl, Br, I, Omesylate, Otosylate, Otriflate
  • R c is: a chiral auxiliary
  • R is: (C ] -C6)-alkyl, or aryl, wherein aryl is defined as phenyl or naphthyl, unsubstituted or substituted as defined hereinbelow.
  • R c is: a chiral auxiliary
  • aryl wherein aryl is defined as phenyl or naphthyl unsubstituted or substituted with one, two or three substitutents defined as R ⁇ , R$ and R ⁇ ;
  • R ! , R 2 , R3, R , R5 an d R6 are independently:
  • R4 and R5 on adjacent carbon atoms can be joined together to form a ring structure:
  • A represents:
  • n 0, 1 or 2;
  • n 2, 3 or 4;
  • s 1 or 2;
  • R7 is:
  • R 8 and R 9 are independently: (a) H, fb) (Cl -C6)-alkyl or (C2-C6)-alkenyl each of which is unsubstituted or substituted with one or two substituents selected from the group consisting of:
  • R7 and R ' 2 0 n the same nitrogen atom they can join together to form a ring selected from the group consisting of: morpholinyl, piperazinyl, or pyrrolyl, or
  • X is Cl, Br, I, Omesylate, Otosylate or Otriflate
  • M+ is Na+, K+, Li+, or NCR 1 6)4+; and R 1 ⁇ is H or (C j - C6)-alkyl;
  • R c is: a chiral auxiliary
  • aryl wherein aryl is defined as phenyl or naphthyl unsubstituted or substituted with one, two or three substitutents defined as R4, R5 and R6;
  • R 1 , R2, R3, R4 5 R5 and R 6 are independently:
  • R4 and R5 on adjacent carbon atoms can be joined together to form a ring structure:
  • A represents:
  • s 1 or 2;
  • Y is-0-,-S(0) n -and-N(Rl2).
  • R 8 and R 9 are independently: (a) H,
  • aryl wherein aryl is defined as phenyl or naphthyl which is unsubstituted or substituted with one or two substituents selected from the group consisting of: i) (Cl-C4)-alkyl, ii) -0-(Cl-C4)-alkyl, iii) -CO[NR7]2, iv) F, Cl, Br or I, v) -COOR7, vi) -NH2, vii) -NH[(Cl -C4)-alkyl], viii) -N[(Cl -C4)-alkyI]2, or ix) -CONICH2CH2I2Q;
  • R7 and R l 2 0 n the same nitrogen atom they can join together to form a ring selected from the group consisting of: morpholinyl, piperazinyl, or pyrrolyl, or
  • Q is O, S or -NR 7 ;
  • X is Cl. Br, 1, Omesylate, Otosylate or Otriflate;
  • M+ is Na+, K+, Li+. or N(R l 6) 4 + ; an d R l 6 is H or (C ⁇ -C5)-alkyl; in an organic solvent at a temperature range of about -60 °C to about 30 °C for about 30 minutes to about 30 hours to give an alkylated derivative bearing the chiral auxiliary:
  • M + is Na + , K + , or Li + ;
  • the alkylation step can be carried out in organic solvents such as tetrahydrofuran, toluene, xylenes, or dimethylforamide.
  • the alkylation step requires the addition of a solution of the salt of the phenoxide generally prepared by the addition of the salt of t-butoxide to a tetrahydrofuran solution of the phenol.
  • N(R 1 6 )4 + , where R 1 6 is defined as H or (C ⁇ -C6)-alkyl] are useful in this alkylation step.
  • the organic solvent is often a mixture of, for example, tetrahydrofuran and t-butanol.
  • the preferred temperature range for the alkylation step is 60 °C to about room temperature (25 °C).
  • the hydrolysis step can be carried out using an inorganic base, such as LiOH, KOH, NaOH, KOCH3, NaOCH3, OCH3, KOC2H5, NaOC2H5, LiOC2H5, etc.
  • the hydrolysis step also requires the presence of a peroxide such as hydrogen peroxide.
  • the aqueous solvent mixtures useful in the hydrolysis step are tetrahydrofuran- water, toluene-water, dimethylformamide-water or alternatively a polar organic solvent such as methanol, ethanol, or t-butanol.
  • An acidic solution such as saturated ammonium chloride solution is useful in the neutralization step.
  • a chiral auxilary is defined as an easily removable chiral group which is attached at a position near the site of alkylation and is capable of influencing the direction of nucleophilic attack.
  • R a is (C l -C6)-alkyl, phenyl, or cyclohexyl
  • R 13 is (C l -C6)-alkyl, phenyl or cyclohexyl
  • R 14 and R l 5 are independently: (C i -C j ⁇ )-alkyl, or R l 4 and R l 5 can join together to form a 5- or 6-membered heterocyclic ring selected from the group consisting of: piperadinyl or pyrrolidinyl.
  • An aspect of this invention is a compound of formula:
  • R a is (Cj -C6)-alkyl, phenyl or cyclohexyl
  • Rl4 and R l 5 are independently: (C ⁇ -C ⁇ o)-alkyl or R l4 and R 1 ⁇ can join together to form a 5- or 6-membered heterocyclic ring
  • 1 5 selected from the group consisting of piperadinyl or pyrrolidinyl.
  • Another aspect of this invention is a compound of formula:
  • X is Cl, Br, I, Omesylate, Otosylate, Otriflate
  • R c is: a chiral auxiliary; R is:
  • aryl wherein aryl is defined as phenyl or naphthyl unsubstituted or substituted with one, two or three substitutents defined as R , R5 a nd R6;
  • R and R ⁇ on adjacent carbon atoms can be joined together to form a ring structure:
  • A represents:
  • n 0, 1 or 2;
  • n 2, 3 or 4;
  • s is I or 2;
  • Y is-O-, -S(0)n-and-N(Rl2)_;
  • R7 and R l 2 0 n the same nitrogen atom they can join together to form a ring selected from the group consisting of: morpholinyl, piperazinyl, or pyrrolyl; and
  • Q is O, S or -NR7.
  • An embodiment of this aspect of the invention is a compound of formula:
  • R c is selected from the group consisting of:
  • R a is (Ci-C6)-alkyl, phenyl or cyclohexyl
  • Rl is (Cl-C6)-alkyl, phenyl or cyclohexyl
  • Rl and Rl5 are independently: (C
  • R is ethyl, phenyl or 3,4-methylenedioxyphenyl.
  • alkyl substituents recited above denote straight and branched chain hydrocarbons of the length specified such as methyl, ethyl, isopropyl, isobutyl, neopentyl, isopentyl, etc.
  • alkenyl-substituents denote alkyl groups as described above which are modified so that each contains a carbon to carbon double bond such as vinyl, allyl and 2-butenyl.
  • Cycloalkyl denotes rings composed of 3 to 8 methylene groups, each of which may be substituted or unsubstituted with other hydrocarbon substituents, and include for example cyclopropyl, cyclopentyl, cyclohexyl and 4-methylcyclohexyl.
  • the alkoxy substituent represents an alkyl group as described above attached through an oxygen bridge.
  • the heteroaryl is defined as carbazolyl, furyl, thienyl, pyrrolyl, isothiazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, purinyl or quinolinyl.
  • the lactamide chiral auxiliary is synthesized from (R)- or
  • lactamide esters of the racemic ⁇ -halo acids were prepared via DCC coupling with commercially available acids or upon reaction with commercially available acid halides according to literature procedure. [See (a) Durst, T.; Koh, K. Tetrahedron Lett. 1992, 33, 6799. (b) Harpp, D.N.; Bao, L.Q.; Black, C.J.; Gleason, J.G.; Smith. R.A.; J. Org. Chem. 1975, 40, 3420.]
  • the coupling reaction was conducted by adding a preformed solution of aryloxide to a THF solution of halide, with or without tricaprylmethylammonium iodide, at the desired temperature (Table 1 ).
  • the reactions were found to proceed at a much faster rate than with conventional ester auxiliaries.
  • a reaction performed at -35 °C with sodium 4-methoxyphenoxide was completed in 0.5h with a diastereoselectivity of 92% (entry 1).
  • a similar reaction utilizing ethyl lactate as the auxiliary required a reaction time of 24h at 0 °C.
  • Product was also obtained with a diminished diastereoselectivity of 60%. This observation also holds true for the ethyl lactate auxiliary.
  • the fact that coupling reactions involving pyrrohdine lactamide auxiliaries proceed at a more rapid rate than their ester counterparts allows for the use of alternative phenoxide salts.
  • Lithium 4-methoxyphenoxide although unreactive at -35 °C, readily undergoes reaction with the ⁇ -bromoester at temperatures ranging from - 15 °C to ambient (entries 3-6). No temperature effect is observed, with diastereoselectivities obtained at room temperature rivaling those obtained with the sodium salt at -35 °C (entries 6-8). However, conducting the coupling reaction utilizing the ⁇ -iodoester leads to significant increases in diastereoselection (entries 9 & 10).
  • the absolute configuration of the newly formed stereogenic center was determined by first hydrolyzing the coupled product to remove the chiral auxiliary, followed by converting the acid to the corresponding R- or S- methyl mandelate. [See Corey, E.J.; Link, J.O. Tetrahedron Lett. 1992, 53, 3431.]
  • ketoester 3 182 g, 0.82 mole
  • methanol 800 ml
  • 5N sodium hydroxide 300 ml
  • water 300 ml
  • the batch was aged for 20 min. during which time a precipitate formed.
  • Methylene chloride 500 ml was added and the mixture was acidified to pH 3.0 using concentrated HCl.
  • the layers were separated and the organic phase was concentrated in vacuo to 100 ml.
  • Toluene (300 ml) was added and concentration was continued to a final volume of 300 ml.
  • the resulting slurry was aged for l h and filtered.
  • the wet cake was washed with hexane and air dried to provide 120 g of ketoacid as a tan solid.
  • ketoacid 80 g, 0.41 moles
  • methylene chloride 800 ml
  • DMF 3 ml
  • the mixture was aged for lh. The batch was quenched into water (500 ml) and the layers separated. The organic layer was washed with water (500 ml) and then with sat'd sodium bicarbonate (2x300 ml). Concentration in vacuo provided 100 g of product as an oil. The material is used in the next step without purification.
  • the mixture was poured into a mixture of brine (200 ml), water (200 ml), and ethyl acetate (400 ml). The layers were cut and the organic layer was concentrated // vacuo to yield 69.0 g of product as an oil.
  • ketoester (44.4 g) in THF (300 ml) was added in water (30 ml).
  • Diastereomeric ratio (DR) determined via HPLC utilizing either a Supelcosil LC CN column or a Chiracel OD column. Diastereoselectivities could also be obtained via 300MHz ] H NMR. Reaction conducted utilizing the ⁇ -iodoester.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
PCT/US1996/019782 1995-12-12 1996-12-09 Stereoselective process WO1997021693A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP09522200A JP2000501737A (ja) 1995-12-12 1996-12-09 立体選択的方法
EP96943713A EP0869950A1 (en) 1995-12-12 1996-12-09 Stereoselective process
AU12878/97A AU703380B2 (en) 1995-12-12 1996-12-09 Stereoselective process

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US875895P 1995-12-12 1995-12-12
US60/008,758 1995-12-12
GB9602833.7 1996-02-13
GBGB9602833.7A GB9602833D0 (en) 1996-02-13 1996-02-13 Stereoselective process
US1328896P 1996-03-12 1996-03-12
US60/013,288 1996-03-12
GB9608928.9 1996-04-29
GBGB9608928.9A GB9608928D0 (en) 1996-04-29 1996-04-29 Stereoselective process

Publications (1)

Publication Number Publication Date
WO1997021693A1 true WO1997021693A1 (en) 1997-06-19

Family

ID=27451397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019782 WO1997021693A1 (en) 1995-12-12 1996-12-09 Stereoselective process

Country Status (5)

Country Link
EP (1) EP0869950A1 (ja)
JP (1) JP2000501737A (ja)
AU (1) AU703380B2 (ja)
CA (1) CA2238960A1 (ja)
WO (1) WO1997021693A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061410A1 (en) * 1998-05-12 1999-12-02 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6310081B1 (en) 1999-05-10 2001-10-30 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6451827B2 (en) 1998-05-12 2002-09-17 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US7091230B2 (en) 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298729A4 (en) * 2008-06-03 2012-12-19 Kaneka Corp PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO ACID DERIVATIVE

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KEVIN KOH ET AL, TERAHEDRON LETTERS, vol. 34, no. 28, 9 July 1993 (1993-07-09), pages 4473 - 4476, XP002026895 *
KEVIN KOH ET AL, TETRAHEDRON LETTERS, vol. 35, no. 3, 17 January 1994 (1994-01-17), pages 375 - 378, XP002026894 *
KEVIN KOH ET AL, THE JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 16, 12 August 1994 (1994-08-12), pages 4683 - 4686, XP002026892 *
PAUL N. DEVINE ET AL, TERAHEDRON LETTERS, vol. 37, no. 16, 15 April 1996 (1996-04-15), pages 2683 - 2686, XP002026896 *
ROBERT D. LARSEN ET AL, J.AM.CHEM.SOC., vol. 111, no. 19, 13 September 1989 (1989-09-13), pages 7650 - 7653, XP002026893 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391897B2 (en) 1998-05-12 2002-05-21 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6451827B2 (en) 1998-05-12 2002-09-17 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6509360B1 (en) 1998-05-12 2003-01-21 Wyeth Penyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999061410A1 (en) * 1998-05-12 1999-12-02 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6369072B2 (en) 1998-05-12 2002-04-09 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US7141672B2 (en) 1998-05-12 2006-11-28 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6214877B1 (en) 1998-05-12 2001-04-10 John A. Butera 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6765021B2 (en) 1998-05-12 2004-07-20 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6844358B2 (en) 1998-05-12 2005-01-18 Wyeth Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US7008636B2 (en) 1998-05-12 2006-03-07 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6310081B1 (en) 1999-05-10 2001-10-30 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US7091230B2 (en) 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
US7495020B2 (en) 2001-02-09 2009-02-24 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Also Published As

Publication number Publication date
AU1287897A (en) 1997-07-03
JP2000501737A (ja) 2000-02-15
CA2238960A1 (en) 1997-06-19
EP0869950A1 (en) 1998-10-14
AU703380B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
JP4231524B2 (ja) 大環状化合物の製造方法
US6444820B1 (en) Process for the manufacture of camptothecin derivatives
EP1254908A1 (en) Preparation of a camptothecin derivative by intramolecular cyclisation
WO1997021693A1 (en) Stereoselective process
KR20110098786A (ko) 말톨 에테르 방법 및 중간체
US5708186A (en) Stereoselective process
US5856519A (en) Chiral auxilary for stereoselective alkylations
JPH07507795A (ja) カンプトテシンおよびカンプトテシン類似体の不斉合成の方法および中間体
KR930010500B1 (ko) 코타르닌의 제조방법
JP2899502B2 (ja) フィソスチグミンからフィソスチグミンカルバメート誘導体を製造する方法
Anacardio et al. Palladium-Catalyzed Selective Carbonylation of Vinyl Triflates in the Presence of 2-Iodophenols: A New Route to 3-Spiro-Fused Benzofuran-2 (3H)-ones
CA2419751A1 (en) A process for the preparation of .alpha.' chloroketones
JP2992334B2 (ja) 軟体動物駆除剤の2,4,5―トリブロモピロール―3―カーボニトリル化合物の製造法
US4386205A (en) Resolution of racemic 5-phenyl-2-pentanol
KR950008527B1 (ko) 피리딘 유도체의 제조방법
Keavy et al. Synthesis of an azide-tethered 4H-furo [3, 4-b] indole
Gimisis et al. A highly efficient synthesis of 3-methylcholanthrene
WO2004060885A1 (ja) 光学活性2−チオメチル−3−フェニルプロピオン酸誘導体およびその合成中間体の製造法
JP2001026591A (ja) アゾニアアダマンタン化合物およびこのものからのアザアダマンタン化合物の製造方法並びに該アゾニアアダマンタン化合物の製造方法
JPS6125716B2 (ja)
EP0873334A1 (en) Process for the preparation of an endothelin antagonist
JP2004331658A (ja) シス−4−シアノシクロヘキサンカルボン酸エステルの製造法
JPH024598B2 (ja)
JP2002544190A (ja) 新規方法
JP2000044566A5 (ja)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996943713

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2238960

Country of ref document: CA

Ref country code: CA

Ref document number: 2238960

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 522200

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996943713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996943713

Country of ref document: EP